The filing is a routine 10b5-1 plan continuation; the CEO has been selling under this plan since August 2026. No new directional signal beyond the existing plan. Monitor for any acceleration of sales outside the plan or changes in insider filing patterns.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $105.35entry
- T+1 · 19h ago −5.80%α −3.89% · $99.24
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
CEO Arjun Agarwal filed a Form 144 notice to sell 29,458 shares valued at approximately $3.16M, representing intent to sell restricted stock acquired via option exercise. The filing is part of an ongoing 10b5-1 plan with multiple prior sales, reducing the signaling impact of this single notice.
Key Facts
- CEO Arjun Agarwal filed Form 144 to sell 29,458 shares of common stock
- Approximate sale value: $3,157,013.86 based on 67,822,359 shares outstanding
- Shares to be sold are acquired upon exercise of stock options over the next three months
- The sale is part of a pre-existing 10b5-1 trading plan with multiple prior sales dating back to August 2026
- Prior 10b5-1 sales include: 10,000 shares on 08/13/2026 ($1.07M), 9,459 shares on 09/11/2026 ($872K), 560 shares on 09/15/2026 ($53.6K), 533 shares on 09/21/2026 ($51K), and 9,999 shares on 10/12/2026 ($806K)
- Company market cap: $7.4B; this sale represents ~0.04% of market cap
Financial Impact
CEO intends to sell ~$3.16M in stock, representing ~0.04% of market cap
Risk Factors
- Insider selling, even under a 10b5-1 plan, may be perceived negatively by some market participants
- CEO has sold ~$2.8M under the plan in the prior three months; continued selling could signal lack of conviction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-011034 |
| Document: 0001950047-26-011034-index.html | 0001950047-26-011034 |
| Document: 0001950047-26-011034.txt | 0001950047-26-011034 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers